Sei Investments Co. purchased a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 56,854 shares of the company’s stock, valued at approximately $849,000. Sei Investments Co. owned about 0.19% of Avalo Therapeutics at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Dimensional Fund Advisors LP acquired a new stake in shares of Avalo Therapeutics in the first quarter valued at approximately $607,000. AlphaCentric Advisors LLC acquired a new position in shares of Avalo Therapeutics during the 1st quarter worth approximately $174,000. Seven Fleet Capital Management LP bought a new stake in Avalo Therapeutics in the 4th quarter valued at $1,150,000. XTX Topco Ltd raised its stake in Avalo Therapeutics by 190.0% in the 4th quarter. XTX Topco Ltd now owns 40,458 shares of the company’s stock valued at $735,000 after acquiring an additional 26,508 shares during the period. Finally, Squadron Capital Management LLC acquired a new stake in Avalo Therapeutics during the 4th quarter valued at $2,361,000. Institutional investors own 87.06% of the company’s stock.
Analyst Ratings Changes
Several analysts recently commented on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th. Mizuho increased their price target on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a report on Thursday, May 14th. Weiss Ratings upgraded shares of Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. HC Wainwright reduced their price objective on Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating for the company in a report on Friday, August 7th. Finally, Citizens Jmp decreased their target price on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research report on Thursday, May 14th. Thirteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Avalo Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $45.10.
Avalo Therapeutics Trading Down 0.5%
Shares of Avalo Therapeutics stock opened at $19.45 on Friday. The firm’s 50 day moving average is $17.69 and its 200 day moving average is $16.41. The firm has a market capitalization of $1.04 billion, a PE ratio of -4.45 and a beta of 0.80. Avalo Therapeutics, Inc. has a 1 year low of $8.41 and a 1 year high of $24.27.
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). As a group, research analysts anticipate that Avalo Therapeutics, Inc. will post -2.59 earnings per share for the current year.
Insider Transactions at Avalo Therapeutics
In related news, insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the completion of the transaction, the insider owned 51,776 shares of the company’s stock, valued at $931,968. This trade represents a 2.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.46% of the company’s stock.
About Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.
Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.
Read More
- Five stocks we like better than Avalo Therapeutics
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Want to see what other hedge funds are holding AVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report).
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
